Adc Therapeutics SA (ADCT)

NYSE
22.18
+0.33(+1.51%)
  • Volume:
    85,994
  • Bid/Ask:
    22.11/22.32
  • Day's Range:
    21.43 - 22.18

ADCT Overview

Prev. Close
21.85
Day's Range
21.43-22.18
Revenue
16.91M
Open
21.75
52 wk Range
20.01-37.82
EPS
-3.28
Volume
85,994
Market Cap
1.69B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
174,690
P/E Ratio
-
Beta
-
1-Year Change
-42.53%
Shares Outstanding
76,754,066
Next Earnings Date
Mar 17, 2022
What is your sentiment on Adc Therapeutics SA?
or
Vote to see community's results!

Adc Therapeutics SA Company Profile

Employees
208

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyStrong SellSell
Technical IndicatorsBuyStrong BuyBuyStrong SellStrong Sell
SummaryBuyStrong BuyBuyStrong SellStrong Sell
  • ofc
    0
    • Looks good!
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.